These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35144181)

  • 21. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.
    Shapiro AE; Ross JM; Yao M; Schiller I; Kohli M; Dendukuri N; Steingart KR; Horne DJ
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013694. PubMed ID: 33755189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages.
    Tukulula M; Gouveia L; Paixao P; Hayeshi R; Naicker B; Dube A
    Pharm Res; 2018 Mar; 35(6):111. PubMed ID: 29600438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.
    Ruslami R; Nijland HM; Adhiarta IG; Kariadi SH; Alisjahbana B; Aarnoutse RE; van Crevel R
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1068-74. PubMed ID: 20038625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia.
    Arega B; Menbere F; Getachew Y
    BMC Infect Dis; 2019 Apr; 19(1):307. PubMed ID: 30947695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
    J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.
    Mtabho CM; Semvua HH; van den Boogaard J; Irongo CF; Boeree MJ; Colbers A; Burger DM; van Crevel R; van der Ven AJAM; Kibiki GS; Tostmann A; Aarnoutse RE
    J Antimicrob Chemother; 2019 Dec; 74(12):3537-3545. PubMed ID: 31651031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
    Ellard GA; Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
    Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
    Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
    Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saquinavir and rifampicin for tuberculosis and AIDS: new considerations.
    Torres TS; Rolla VC
    Int J Tuberc Lung Dis; 2006 Nov; 10(11):1302; author reply 1302-3. PubMed ID: 17131794
    [No Abstract]   [Full Text] [Related]  

  • 34. Conflicting reports on the role of the glycemic effect of Catha edulis (Khat): A systematic review and meta-analysis.
    Alsalahi A; Alshawsh MA; Mohamed R; Alyousefi NA; Alshagga MA; Shwter AN; Al-Maqtari A; Ahmed RH; Mohamed Z
    J Ethnopharmacol; 2016 Jun; 186():30-43. PubMed ID: 27025406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
    Rekić D; Röshammar D; Mukonzo J; Ashton M
    Br J Clin Pharmacol; 2011 Apr; 71(4):536-43. PubMed ID: 21395646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Importance of Therapeutic Drug Monitoring of Rifampicin.
    Chawla PK; Udwadia ZF; Soman R; Mahashur AA; Amale RA; Dherai AJ; Lokhande RV; Naik PR; Ashavaid TF
    J Assoc Physicians India; 2016 Aug; 64(8):68-72. PubMed ID: 27762112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability studies of rifampicin in plasma and urine of tuberculosis patients according to the European Medicines Agency Guidelines.
    Mishra P; Pawar RP; Bose D; Durgbanshi A; Albiol-Chiva J; Peris-Vicente J; Esteve-Romero J; Jain A
    Bioanalysis; 2019 Apr; 11(8):713-726. PubMed ID: 30994011
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
    Oudijk JM; McIlleron H; Mulenga V; Chintu C; Merry C; Walker AS; Cook A; Gibb DM; Burger DM
    AIDS; 2012 Jul; 26(12):1523-8. PubMed ID: 22546991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
    van Crevel R; Alisjahbana B; de Lange WC; Borst F; Danusantoso H; van der Meer JW; Burger D; Nelwan RH
    Int J Tuberc Lung Dis; 2002 Jun; 6(6):497-502. PubMed ID: 12068982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
    AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.